Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...
Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist
Truist lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $18 from $21 but keeps a Buy rating on the shares after its Q4 results ...
Morningstar11d
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s ...
Finanznachrichten11d
Y-mAbs Therapeutics, Inc.: Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
manilatimes11d
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company's ...
Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clin ...
BioSpace9d
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s ...
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025
USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never ...
Medscape9d
Study Charts Success in Elderly Lymphoma Tx
Real-world treatment patterns and outcomes among older patients with follicular lymphoma show significant heterogeneity, with 13,423 Medicare beneficiaries aged ≥ 65 years followed through 2019 ...
Medical News Today16d
What to know about Medicare coverage for radiation therapy
Original Medicare Part A covers radiation therapy received as an inpatient in the hospital, Part B covers radiation therapy received as an outpatient in a clinic, and Part D may cover oral ...
Frontiers20d
Novel anti-cancer drugs combination radio-immunotherapy strategy: new frontiers in cancer immunotherapy
In recent years, traditional surgery, chemotherapy, and radiotherapy alone may fail to acquire satisfactory effects for patients. However, radiotherapy combined with immunotherapy will enhance the ...